LeonaBio, Inc. Accretion Expense
LeonaBio, Inc. (LONA) reported Accretion Expense of $289.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2021-05-13
- LeonaBio, Inc. accretion expense for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
- LeonaBio, Inc. accretion expense for the quarter ending 2020-03-31 was $172.00K.
- LeonaBio, Inc. accretion expense for the quarter ending 2019-12-31 was $83.00K.
- LeonaBio, Inc. accretion expense for fiscal 2020 was $289.00K, a 12.02% increase from fiscal 2019.
- LeonaBio, Inc. accretion expense for fiscal 2019 was $258.00K.
| Period end | Accretion Expense 3 month | Accretion Expense 6 month | Accretion Expense 9 month | Accretion Expense 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $289.00K 10-K · filed 2021-03-25 | ||
| 2020-09-30 | $289.00K 10-Q · filed 2020-11-12 | |||
| 2020-03-31 | $172.00K 10-Q · filed 2021-05-13 | $255.00K derived: sum of 2 quarters · filed 2021-05-13 | ||
| 2019-12-31 | $83.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $258.00K 10-K · filed 2021-03-25 | ||
| 2019-09-30 | $175.00K 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |